Quick Facts

• Relieves and Prevents: Sudden, severe joint pain episodes caused by gout attacks.
• Addresses: The inflammatory condition known as Familial Mediterranean Fever (FMF).
• Reduces Risk: Of major cardiac events, including heart attack, stroke, and cardiovascular death, in adults with established atherosclerotic disease or multiple risk factors.

---

Colchicine Tiofarma is a medicine used to manage several inflammatory conditions. Its primary uses are to treat acute gout flares and to prevent gout attacks in adults. Gout involves episodes of sharp joint pain resulting from elevated uric acid levels.

The medication is also indicated for the treatment of Familial Mediterranean Fever (FMF) in adults and children four years of age and older. FMF is a hereditary disorder that causes recurring episodes of inflammation and fever.

Furthermore, a key benefit of colchicine is its role in cardiovascular risk reduction. It is approved to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death, in patients with established atherosclerotic cardiovascular disease or with multiple risk factors.

Regulatory References

1. NIH MedlinePlus guidance

This section summarizes the official eligibility and non-eligibility information for Colchicine Tiofarma based on authoritative governmental regulatory documents. The medicine is subject to strict limitations and absolute prohibitions.

Populations Excluded (Contraindicated)

Use of this medicine is strictly prohibited (contraindicated) in patients with:

• Severe Renal Impairment (severe kidney failure).
• Severe Hepatic Dysfunction (severe liver disease).
• Pre-existing Blood Dyscrasias (e.g., leukopenia, aplastic anemia).
• Known Hypersensitivity (allergy) to colchicine or any of the inactive ingredients.

Critical Restriction for Organ Impairment and Drug Interactions

Colchicine Tiofarma is also contraindicated in any patient (regardless of severity) who has renal or hepatic impairment and is concurrently taking specific strong P-glycoprotein (P-gp) and/or CYP3A4 inhibitors. This combination carries a risk of life-threatening toxicity due to significant increases in colchicine blood levels.

Specific Population Rules

• Pediatric Use: The use of the medicine is generally restricted in children. For the treatment of Familial Mediterranean Fever (FMF), some regulatory labels permit use only in children 4 years of age and older.
• Pregnancy and Lactation: Use is contraindicated in pregnant women and women who are breastfeeding according to certain regulatory documents, due to potential risks.
• Geriatric Patients: Older and debilitated patients may have increased susceptibility to toxicity, necessitating careful monitoring or dose adjustments, particularly in the presence of impaired kidney function.

Interactions with other medicines and products

The official regulatory documents define the product’s interaction structure primarily through its clearance pathways. Colchicine is classified as a substrate for both the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter. Inhibition of these pathways constitutes a pharmacokinetic interaction that significantly raises systemic colchicine exposure.

Contraindicated Combinations

The co-administration of colchicine with strong CYP3A4 inhibitors and/or P-gp inhibitors is formally classified as Contraindicated in patients with pre-existing Renal Impairment or Hepatic Impairment. This population-specific restriction is based on the official determination that impaired function, combined with inhibition, can lead to uncontrolled accumulation and risk of life-threatening toxicity.

Pharmacodynamic Interactions

The regulatory profile notes an increased risk of myopathy (muscle disease) and rhabdomyolysis when colchicine is combined with other medicines known to cause muscle toxicity. This includes co-administration with HMG-CoA Reductase Inhibitors (Statins) and Fibrates, creating a pharmacodynamic synergism.

Food and Substance Restriction

The consumption of Grapefruit or Grapefruit Juice is explicitly restricted in the labeling. These products act as inhibitors of CYP3A4 and P-gp, and their co-ingestion is documented to increase the systemic exposure of colchicine. Furthermore, colchicine may cause reversible malabsorption of Vitamin B12.

The mechanism of action for colchicine involves two unique and interconnected processes that modulates the cellular components of the acute inflammatory process.

Inhibition of Microtubule Function and Cellular Migration

Colchicine exerts its primary mechanistic effect by binding to the protein tubulin, thereby inhibiting the assembly of microtubules—essential components of the cell's internal structure. This disruption impairs the function of leukocytes, such as neutrophils, to perform crucial processes like chemotaxis (directed movement) and phagocytosis. This action restricts the accumulation of these cells at the site of inflammatory activity, thereby modulating an early step in the acute inflammatory cascade.

Suppression of Inflammasome Activation and Cytokine Release

The drug's structural interference extends to molecular signaling by indirectly blocking the activation of the NLRP3 inflammasome complex. By preventing the assembly of this complex, colchicine reduces the subsequent processing and secretion of pro-inflammatory chemical messengers, most notably Interleukin-1 beta (IL-1beta). The combination of cellular immobilization and signaling suppression results in the modulation of the localized acute inflammatory response, defining the resulting physiological effect of the drug's mechanism.

How to Use Colchicine Tiofarma

Colchicine Tiofarma is intended for administration exclusively by the oral route (by mouth), typically supplied as a tablet or capsule. The official administration protocol is structured based on whether the treatment is for a sudden, acute episode or for long-term daily maintenance.

Official Dosing and Administration Principles

Context	Regimen & Frequency	Special Instructions
Acute Gout Flare	Initial dose of 1.2 mg followed by 0.6 mg one hour later (US-aligned), or 1 mg then 0.5 mg after one hour (EU-aligned).	The total single-course dose must not exceed the prescribed limit, and a course should not be repeated for at least 3 days (72 hours).
Prophylaxis/Maintenance	0.5 mg to 1.2 mg total daily dose, administered once or twice daily.	For maintenance, if a dose is missed, it should be skipped if close to the next scheduled time; double doses are prohibited.
FMF (Adults)	1.2 mg to 2.4 mg total daily dose, given once or in two divided doses.	Dose adjustments for FMF are typically made in increments or decrements of 0.3 mg/day.

Tablets should be swallowed whole with water and may be taken without regard to meals. Following an acute treatment course, patients on maintenance therapy must wait 12 hours before resuming their regular daily prophylactic dose. Labeled dosing requires adjustment for patients with severe kidney or liver impairment, and the regimen must be modified when taken with certain other medications.

Research evidence / Overview of studies for Colchicine Tiofarma

The clinical evaluation of this medicine is supported by research conducted across its main areas of study. This overview describes what scientific research has explored, what patterns have been observed, and where gaps or uncertainties remain, according to official regulatory and peer-reviewed sources.

---

Evidence for Use in Acute Gout Flares and Prevention

Research for acute gout flares relies on short-term, comparative studies and Randomized Controlled Trials (RCTs) used to explore how outcomes related to physical discomfort change over very short time intervals. Findings describe that one low-dose regimen was associated with the observation of a higher proportion of participants recording a measured change in pain intensity compared to a placebo. Other trials compared to different anti-inflammatory treatments reported similar measured outcomes.

For prophylaxis against future gout attacks, long-term RCTs and retrospective studies were used. These studies monitored outcomes such as the frequency of gout flares. Evidence is limited regarding the patterns of repeated, short-term use for sequential gout flares.

---

Evidence for Use in Familial Mediterranean Fever (FMF)

The research base for Familial Mediterranean Fever (FMF) is characterized by long-term observational studies and systematic reviews. Studies examined outcomes such as the prevention of recurrent fever and inflammatory attacks, as well as the long-term risk of developing amyloidosis. Studies reported that the long-term administration was associated with the pattern of a lower reported rate of amyloidosis. Clinical data also shows patterns related to a minority of patients being considered to have an inadequate response to the treatment, and research into the best approach for this minority is still emerging. Data for children four years of age and older were included in FMF studies.

---

Evidence for Cardiovascular Risk Reduction

Evidence for studying cardiovascular risk relies on large-scale, placebo-controlled RCTs, such as COLCOT and LoDoCo2. These studies monitored the occurrence of composite Major Adverse Cardiovascular Events (MACE). Multiple large RCTs studies observed patterns related to a lower rate of the composite MACE outcome in the studied population when compared to the placebo group. However, analyses of the individual components did not report a statistically significant finding related to cardiac death or all-cause mortality during the follow-up period.

---

What is Still Uncertain About Colchicine Tiofarma Research

Key limitations exist in the broader evidence landscape. Long-term effects for the cardiovascular indication are not fully established beyond the trial follow-up periods. Comparative evidence is lacking for many scenarios. Data for certain special populations, such as pregnant populations, remain insufficient. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Colchicine Tablets USP, 0.6 mg Full Prescribing Information (Indications for FMF, Gout Flares, and Cardiovascular Risk Reduction)

Common questions about Colchicine Tiofarma (FAQ)

Q: What is Colchicine Tiofarma used for?

Colchicine Tiofarma is used in adults for the short-term treatment of acute gout attacks and for the prevention of gout attacks.

Q: What is gout?

Gout is a type of inflammatory arthritis caused by the build-up of uric acid crystals in the joints, most commonly affecting the big toe, but it can affect other joints. This build-up causes sudden, severe attacks of pain, swelling, and redness.

Q: How does Colchicine Tiofarma work?

Colchicine Tiofarma is an anti-gout agent. It works by reducing the inflammation and pain associated with an acute gout attack. Although the exact mechanism of action related to gout is complex, it is known to interfere with certain inflammatory processes in the body.

Q: How long does it take for Colchicine Tiofarma to work for an acute gout attack?

When taken for an acute gout attack, you may start to feel relief from pain and inflammation within 12 to 24 hours, with symptoms often improving significantly within 48 hours.

Q: What are the common side effects of Colchicine Tiofarma?

The most common side effects are related to the digestive system and include nausea, vomiting, diarrhea, and abdominal pain. These effects are often signs that the maximum tolerated dose has been reached. Less common but serious side effects can affect the blood, liver, and muscles.

Q: Can I take Colchicine Tiofarma with other medicines?

Colchicine Tiofarma can interact with many other medicines. It is very important to tell your doctor or pharmacist about all the medicines you are taking, including over-the-counter drugs and herbal supplements, as some combinations can increase the risk of side effects, particularly muscle weakness and blood disorders. Specific drugs that are often a concern include certain antibiotics, antifungals, and cholesterol-lowering medicines (statins).

Q: What should I do if I miss a dose?

If you are taking Colchicine Tiofarma for gout prevention and miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. Follow your doctor's specific advice.

Q: Can Colchicine Tiofarma be used by pregnant or breastfeeding women?

Colchicine Tiofarma is not usually recommended during pregnancy or breastfeeding. It is important to discuss your specific situation with your doctor, who will weigh the potential benefits against the possible risks. Effective contraception should be used by women of childbearing potential during treatment.

Q: Should I change my diet while taking Colchicine Tiofarma?

While taking Colchicine Tiofarma, managing your diet is a key part of managing your underlying gout condition. You should aim to limit foods high in purines (like red meat, organ meat, and some seafood) and avoid excessive alcohol intake, particularly beer. Your doctor or a nutritionist can provide personalized dietary recommendations to help prevent future gout attacks.

Storage Requirements

Labeled Storage Temperature Requirements	Not exceeding 25 C
Light Protection and Packaging Rules	Protect from light; store in the original package
Child-Safety Storage	Must be kept out of the sight and reach of children
Stability After Opening	Shelf life after the first opening of the tablet container is 6 months

Disposal Instructions

Disposal Method Restrictions	Must not be thrown away via wastewater or household waste
Official Procedure	Ask a pharmacist how to throw away unused medicines
Environmental Requirement	These measures are mandatory to help protect the environment

The official regulatory profile strictly mandates that Colchicine Tiofarma be stored below 25 C and kept in the original container to protect the tablets from light. A critical stability constraint is the 6-month limit for use after the tablet container is first opened. Due to the high potency of the medicine, it must be stored securely out of children's reach. Proper disposal requires returning expired or unused medicine to a pharmacist, as it must not be discarded in household trash or down the drain.